HC Wainwright Reiterates Buy Rating for Cocrystal Pharma (NASDAQ:COCP)

Cocrystal Pharma (NASDAQ:COCP)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $7.00 price objective on the stock. HC Wainwright’s price objective would indicate a potential upside of 239.81% from the company’s current price.

Cocrystal Pharma Stock Performance

COCP stock opened at $2.06 on Wednesday. The stock has a market capitalization of $20.95 million, a price-to-earnings ratio of -1.11 and a beta of 1.53. Cocrystal Pharma has a 1 year low of $1.33 and a 1 year high of $3.26. The stock’s fifty day moving average is $2.16 and its two-hundred day moving average is $1.99.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.